Snowball logo
logo
ZLDA_logo

Zelira Therapeutics Limited

ZLDAF • OTCQB
$0.26$0.00  (0%)
Estimate
EPS
-0.2
Beta
0.61
About the company
Ticker
ZLDAF
ISIN
Country
Australia
Sector (GICS)
Healthcare
Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment of chronic insomnia. The company also provides over the counter (OTC) products, including SprinJeneCBD, an oral care product; and acne treatment products under the RAF FIVE name, as well as Zyraydi, an enhanced distillate capture and dissolution matrix technology. In addition, it offers products for autism and chronic noncancer pain. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited was incorporated in 2003 and is based in Perth, Australia.

Frequently asked questions

What sector does Zelira Therapeutics Limited (ZLDAF) operate in?

Zelira Therapeutics Limited belongs to the Healthcare sector and operates in the Biotechnology industry.

What is Zelira Therapeutics Limited (ZLDAF) current stock price?

As of the latest data, Zelira Therapeutics Limited stock price is $0.26, with a previous close of $0.26.

What is Zelira Therapeutics Limited (ZLDAF) current market capitalization?

Zelira Therapeutics Limited market cap is approximately 3.42 million.

What is Zelira Therapeutics Limited (ZLDAF) Earnings Per Share (EPS)?

The trailing EPS is -$0.20.

Does Zelira Therapeutics Limited (ZLDAF) pay dividends?

No. Zelira Therapeutics Limited does not pay a dividend.

What is Zelira Therapeutics Limited (ZLDAF) beta (volatility) score?

Zelira Therapeutics Limited has a beta of 0.610, indicating lower volatility than the overall market.